Indication
  • Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

Although uncommon, Meningococcal group B disease (MenB) is caused by bacteria that is spread through common adolescent behavior, like sharing cups or utensils, and communal living. Symptoms often seem like the flu, but can become deadly within just 24 hours.1-3

Potentially deadly or debilitating consequences for survivors 1 & 7

Death within 24 hours

Scarring

Loss of limbs

Hearing loss

Brain damage

Loss of vision

The risk of meningitis B (also known as MenB)

Prevalence of MenB

MenB represents 50% of all meningococcal disease cases among adolescents and young adults in the US.3

Serious and sudden

On average, 1 in 10 adolescents and young adults who develop MenB will die from it – some within 24 hours.1 & 5

Are you sure your child is protected?

Even if your child has been vaccinated for meningococcal disease (MCV4), he or she may not be vaccinated against MenB. Before 2014, there were no approved vaccines in the US for MenB.6

Trumenba is an FDA-approved vaccine for meningococcal group B disease (also known as meningitis B) in those 10 through 25 years of age.8
The Centers for Disease Control and Prevention (CDC) recommends that a meningitis B vaccine may be administered to adolescents and young adults.4

What happens when a child contracts MenB?

Trumenba is an FDA-approved vaccine for meningococcal group B disease (also known as meningitis B) in those 10 through 25 years of age.8
The Centers for Disease Control and Prevention (CDC) recommends that a meningitis B vaccine may be administered to adolescents and young adults.4

Talk to a doctor about Trumenba

TRUMENBA is available from many healthcare providers and pharmacists.
Talk to a healthcare provider about vaccinating your child with TRUMENBA.
Find out where to get TRUMENBA.
Call 1-800-683-8572.

How much will this cost?

Find out if your insurance will pay for TRUMENBA.
Call 1-866-744-3198 Mon-Fri 9 AM-7 PM ET

Important Safety Information and Indication
Indication
  • Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
Important Safety Information
  • Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
  • Individuals with weakened immune systems may have a reduced immune response
  • The most common adverse reactions in adolescents and young adults were pain at the injection site, fatigue, headache, and muscle pain
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant
  • Ask your healthcare provider about the risks and benefits of Trumenba. Only a healthcare provider can decide if Trumenba is right for you or your child

Call 1-844-TRUMENBA (878-6362), 9 am to 7 pm ET, Monday through Friday, for more information.

Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

References:
  1. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
  2. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. Updated March 4, 2016. Accessed November 1, 2016.
  3. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college―Rhode Island, 2015. MMWR. 2015;64(22):606-607.
  4. MacNeil JR, Rubin L, Folaranmi T, et al. Centers for Disease Control and Prevention. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-•‐1176.
  5. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191.
  6. Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015; 64(22):608-612.
  7. Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20-e25.
  8. Trumenba prescribing information. Philadelphia, PA: Pfizer Inc; 2017.

PP-TRU-USA-1294-01